Document Detail

Innate immunity and alcoholic liver disease.
MedLine Citation:
PMID:  23075869     Owner:  NLM     Status:  MEDLINE    
Innate immunity provides the primary response to danger signals from pathogens or injured host cells and tissues. The cells of the innate immune system include monocytes, macrophages, dendritic cells, neutrophils, NK cells and NKT cells that orchestrate innate immune and initiate adaptive immune responses via cell interactions, cytokines, chemokines and other mediators. The most robust and common response of the innate immune system to danger signals is inflammation. In the multifactorial pathophysiology of alcoholic liver disease (ALD), activation of innate immune cells and the inflammatory cascade play a central role. Recent studies have demonstrated that Toll-like receptors (TLRs), the sensors of microbial and endogenous danger signals, are expressed and activated in innate immune cells as well as in parenchymal cells in the liver, and thereby contribute to ALD. The importance of gut-derived endotoxin and its recognition by TLR4 expressed on innate immune cells and liver parenchymal cells and the specificity of TLR4-induced downstream signaling via the interferon regulator factor 3 (IRF3) has recently been investigated. We have shown that mice deficient in IRF3 or TLR4 expression are protected from alcohol-induced liver steatosis, inflammation and hepatocyte injury. In addition to pathogen-derived danger molecules, the inflammatory cascade can also be activated by endogenous danger signals released from damaged cells. The inflammasome, a multiprotein complex, senses endogenous danger molecules to result in caspase-1-mediated cleavage of IL-1β. Our recent results suggest that inflammasome and caspase-1 activation occur in ALD and that IL-1 significantly contributes to both steatosis and inflammation in the liver in ALD.
Gyongyi Szabo; Jan Petrasek; Shashi Bala
Related Documents :
24213679 - Regulatory t cell subsets in human cancer: are they regulating for or against tumor pro...
23341789 - The blocking of c-met signaling induces apoptosis through the increase of p53 protein i...
24846129 - An approach to control relapse of inflammatory lesions after discontinuation of primary...
23225169 - Smac mimetic birinapant induces apoptosis and enhances trail potency in inflammatory br...
23953289 - Hydrogen peroxide induces apoptosis in human dental pulp cells via caspase-9 dependent ...
23623189 - Neuropeptide y induces secretion of high-mobility group box 1 protein in mouse macropha...
8141289 - Neuroimmune signaling in regulation of intestinal ion transport.
16080799 - Effects of alpha fetoprotein on escape of bel 7402 cells from attack of lymphocytes.
16325779 - Simvastatin induces caspase-independent apoptosis in lps-activated raw264.7 macrophage ...
Publication Detail:
Type:  Journal Article; Research Support, N.I.H., Extramural; Review     Date:  2012-10-11
Journal Detail:
Title:  Digestive diseases (Basel, Switzerland)     Volume:  30 Suppl 1     ISSN:  1421-9875     ISO Abbreviation:  Dig Dis     Publication Date:  2012  
Date Detail:
Created Date:  2012-10-18     Completed Date:  2013-05-29     Revised Date:  2013-06-05    
Medline Journal Info:
Nlm Unique ID:  8701186     Medline TA:  Dig Dis     Country:  Switzerland    
Other Details:
Languages:  eng     Pagination:  55-60     Citation Subset:  IM    
Copyright Information:
Copyright © 2012 S. Karger AG, Basel.
Department of Medicine, University of Massachusetts Medical School, Worcester, MA 01605, USA. Gyongyi.Szabo @
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Immunity, Innate / immunology*
Inflammation / genetics,  pathology
Interleukin-1 / immunology
Kupffer Cells / immunology,  pathology
Liver Diseases, Alcoholic / genetics,  immunology*,  therapy
MicroRNAs / genetics,  metabolism
Grant Support
Reg. No./Substance:
0/Interleukin-1; 0/MicroRNAs

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  NK cells in hepatitis C: role in disease susceptibility and therapy.
Next Document:  Nonalcoholic Fatty liver disease: what the pathologist can tell the clinician.